a consensus criteria time for full efficacy assessment set by the International Myeloma Working Group (IMWG), and found that 14 reached stringent complete response (sCR) criteria, which means there is no detectable plasma cells in the patient's bone marrow or myeloma proteins in the serum...
Aurore PerrotClinical Haematology Unit Cancer University Institute of Toulouse – Oncopole Toulouse FranceInes VergnolleHaematology LaboratoryCancer University Institute of Toulouse – Oncopole ToulouseFranceAnais SchavgoulidzeHaematology LaboratoryCancer University Institute of Toulouse – Oncopole ToulouseFrance...
Richard L.LeakeMD, ...Christopher J.HanrahanMD, PhD, inRadiologic Clinics of North America, 2019 Multiple Myeloma Multiple myelomais a heterogeneous group of malignantplasma cell neoplasmscharacterized by uncontrolled proliferation of clonal plasma cells in the bone marrow.Multiple myelomaaccounts for ap...
Immune System – Structure and Function Pathogenesis of Multiple Myeloma Plasma cells are activated B lymphocytes. Normally, antigens present on the surface of infecting organisms or tumor cells cause activation of B lymphocytes to form plasma cells. However, in multiple myeloma, plasma cells are for...
Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the past few years have led to improved outcomes and longer survival, MM remains largely incurable. Over the past decade, genomic ana...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
Plasma cells in Multiple Myeloma express a natural killer cell-associated antigen:CD56 (NKH-1; Leu19) Bone marrow samples from 55 patients with multiple myeloma (MM) and 23 patients with monoclonal gammopathy of undertermined significance (MGUS) were evaluated with a broad panel of monoclonal ...
Multiple myeloma is a cancer caused by the abnormal proliferation of plasmacells,white blood cellsproducing antibodies, in the bone marrow. Scientists from the Institut Pasteur and Inserm, in collaboration with the University of Paris and the Saint Louis Hospital (AP-HP) describe a new mechanism ...
Multiple myeloma (MM) is the second most common hematological malignancy in the US1, characterized by the clonal expansion of plasma cells localized primarily in the bone marrow microenvironment of the skeleton2,3. In the bone microenvironment, MM cells disrupt the finely tuned balance of trabecular...
浆细胞病(Plasma cell dyscrasias) 多发性骨髓瘤(Multiple Myeloma)定义和特性;What Is Multiple Myeloma?;浆细胞病(Plasma cell dyscrasias);隐性浆细胞病良性单克隆免疫球蛋白血症;继发性单克隆免疫球蛋白血症。病因:尚未完全明了可能与遗传有关,有染色体异常病毒感染继发于其他疾病(慢性骨髓炎、结核、慢性肝炎);M...